<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337112</url>
  </required_header>
  <id_info>
    <org_study_id>VILT-501</org_study_id>
    <nct_id>NCT04337112</nct_id>
  </id_info>
  <brief_title>The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation</brief_title>
  <official_title>The Expanded Access Use of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy (DMD) Amenable to Exon 53 Skipping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NS Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NS Pharma, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open label expanded access program for boys, 3 to 12 years old, for the treatment&#xD;
      of Duchenne muscular dystrophy (DMD) with confirmed mutation(s) in the dystrophin gene that&#xD;
      is amenable to skipping of exon 53.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This expanded access program is designed to provide access to viltolarsen in patients with&#xD;
      DMD with confirmed mutation(s) in the dystrophin gene amenable to skipping of exon 53, who in&#xD;
      the opinion and clinical judgement of the treating physician, would benefit from treatment&#xD;
      with viltolarsen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <condition>DMD</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>viltolarsen</intervention_name>
    <description>Intravenous (IV) infusions, weekly, at 80mg/kg, once weekly (approximately every 7 days).</description>
    <other_name>NS-065/NCNP-01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male ≥ 3 and ≤ 12 years of age&#xD;
&#xD;
          -  Clinical signs compatible with DMD&#xD;
&#xD;
          -  Confirmed DMD mutation(s) in the dystrophin gene that is amenable to skipping of exon&#xD;
             53 to restore the dystrophin messenger ribonucleic acid (mRNA) reading frame&#xD;
&#xD;
          -  Able to walk independently without assistive device&#xD;
&#xD;
          -  Not able to participate in a Phase 3 trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic systemic fungal or viral infections&#xD;
&#xD;
          -  An acute illness within 4 weeks prior to the first dose of viltolarsen&#xD;
&#xD;
          -  Symptomatic cardiomyopathy&#xD;
&#xD;
          -  Patient has a previous or ongoing medical condition, medical history, physical&#xD;
             findings, or laboratory abnormality that could affect participant safety in the&#xD;
             opinion of the treating physician&#xD;
&#xD;
          -  Surgery within the 3 months prior to the first anticipated administration of&#xD;
             viltolarsen and in the opinion of the treating physician would impact weekly treatment&#xD;
             schedule&#xD;
&#xD;
          -  Positive test results for hepatitis B antigen, hepatitis C antibody, or human&#xD;
             immunodeficiency virus (HIV) antibody at screening&#xD;
&#xD;
          -  Currently taking any other investigational drug or has taken any other investigational&#xD;
             drug within 3 months prior to the first dose of viltolarsen&#xD;
&#xD;
          -  Previously enrollment in any viltolarsen study.&#xD;
&#xD;
          -  Currently taking any other exon skipping agent or has taken any other exon skipping&#xD;
             agent within 2 weeks prior to the first dose of viltolarsen (would need to be&#xD;
             discontinued in order to be eligible)&#xD;
&#xD;
          -  Any gene therapy for DMD&#xD;
&#xD;
          -  Inadequate renal function as defined by a serum cystatin C &gt; 1.5 x upper limit of&#xD;
             normal (ULN). If the value is &gt; 1.5 x ULN then the measurement can be repeated once.&#xD;
             If repeat measurement is still &gt; 1.5 x ULN then the patient should be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Muscular Dystrophies</keyword>
  <keyword>Muscular Dystrophy, Duchenne</keyword>
  <keyword>Muscular Disorders, Atrophic</keyword>
  <keyword>Muscular Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Neuromuscular Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Genetic Diseases, X-Linked</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

